Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

2.92USD
14 Dec 2017
Change (% chg)

$-0.06 (-2.01%)
Prev Close
$2.98
Open
$2.98
Day's High
$3.02
Day's Low
$2.88
Volume
328,897
Avg. Vol
260,287
52-wk High
$4.07
52-wk Low
$2.20

Chart for

About

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the... (more)

Overall

Beta: 2.71
Market Cap(Mil.): $397.08
Shares Outstanding(Mil.): 135.99
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 190.77 15.47
EPS (TTM): -- -- --
ROI: -- -11.61 33.71
ROE: -- -35.87 16.38

BRIEF-Celldex Therapeutics initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma

* Celldex Therapeutics Inc initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma Source text for Eikon: Further company coverage:

Nov 17 2017

BRIEF-Celldex Therapeutics Q3 loss per share $0.20

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

Nov 07 2017

BRIEF-Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

* Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

Aug 23 2017

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million

Aug 08 2017

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Aug 08 2017

BRIEF-Celldex Therapeutics promotes Sam Martin as CFO

* Celldex Therapeutics announces additions to the board of directors and senior management team

Jun 16 2017

Earnings vs. Estimates